
Nazanin Majd, MD, PhD
@nazmajd
Assistant Professor of Neuro-Oncology, MD Anderson Cancer Center. Tweets are my own.
ID: 1241556004007030784
22-03-2020 02:43:27
100 Tweet
244 Followers
265 Following


Congratulations! Hussein Tawbi, MD, PhD and team! MD Anderson Cancer Center Treatment advances in melanoma inspire all oncologists! #EndCancer

Our updated Immunotherapy for Neuro-Oncology chapter is now available online! MD Anderson Cancer Center Soecial thanks to John de Groot, MD, Pushan Dasgupta, Aung Naing, Joud Hajjar MD, PhD, MS: pubmed.ncbi.nlm.nih.gov/34972967/


Congratulations! Your proud sister and mentee! ❤️Reza Majdzadeh

Enjoyed reading this article by my amazing colleague and friend, Ashley Aaroe, MD. Our field is lucky to have you as our patients’ advocate! #neurology, #braintumor, MD Anderson Cancer Center neurologylive.com/view/neurology…


Two of my favorite leaders committed to #endcancer! You are our source of inspiration! @DrAlfredYung , MD Anderson Cancer Center



It was my honor and a privilege to present the highlights of CNS tumors at #ASCO2023! Specially, highlighting the historical study by Dr. Mellinghoff and colleagues. nejm.org/doi/full/10.10…. Thank you ASCO organizers! MD Anderson Cancer Center

Our newly activated trial is specifically designed for patients with oligodendroglioma (CIC mutated) and NF1-associated gliomas clinicaltrials.gov/ct2/show/NCT05…. Excited to announce this unique trial and accrue patients! #endcancer, MD Anderson Cancer Center

DDR 🤴!!! The Taylor Swift of Oncology!!! The man the myth……………Tim Yap!! MD Anderson Cancer Center #ASCO24



Do you have a newly diagnosed GBM, MGMT unmethylated patient who would benefit from more resection? We have a clinical trial opportunity for them. mdanderson.org/patients-famil… #endcancer MD Anderson Cancer Center

Do you have a newly diagnosed GBM patient, MGMT unmethylated with KIT or PDGFRA alterations? Phase 2 trial of avapritinib at MDA would provide an opportunity for upfront targeted therapy after chemoRT. Please reach out if you have trial candidates. MD Anderson Cancer Center Stacie Walker

Exciting trial for patients with low grade gliomas! - We are targeting ERK for treatment of recurrent oligodendroglioma and NF1-associated low-grade glioma using ulixertinib in our surgical trial clinicaltrials.gov/study/NCT05804…. MD Anderson Cancer Center #endcancer